Indisulam
Indisulam Basic information
- Product Name:
- Indisulam
- Synonyms:
-
- INDISULAM
- 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-
- N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide
- E-7070
- ER-35744
- IndisulaM (E7070)
- IndisulaM (E7070) (ER-35744)
- N1-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
- CAS:
- 165668-41-7
- MF:
- C14H12ClN3O4S2
- MW:
- 385.85
- Mol File:
- 165668-41-7.mol
Indisulam Chemical Properties
- Melting point:
- 242-243 °C (decomp)(Solv: ethanol (64-17-5); water (7732-18-5))
- Boiling point:
- 668.9±65.0 °C(Predicted)
- Density
- 1.663±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- DMSO : 100 mg/mL (259.17 mM; Need ultrasonic)
- form
- powder
- pka
- 8.14±0.30(Predicted)
- color
- white to beige
- InChI
- InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
- InChIKey
- SETFNECMODOHTO-UHFFFAOYSA-N
- SMILES
- C1(S(NC2C3=C(C=CC=2)C(Cl)=CN3)(=O)=O)=CC=C(S(N)(=O)=O)C=C1
Indisulam Usage And Synthesis
Uses
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15[1][2].
Definition
ChEBI: Indisulam is a chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor and an antineoplastic agent. It is a chloroindole, a sulfonamide and an organochlorine compound.
Biochem/physiol Actions
Indisulam is a carbonic anhydrase inibitor and Antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition.
in vivo
Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models[1].
| Animal Model: | Female BALB/c nu/nu mice aged 7 weeks (HCT116 colon, LX-1 lung, SW620 colon, HCT115 colon, PC-9 lung, DLD-1 colon and WiDr colon models)[1]. |
| Dosage: | 12.5, 25, 50 (100) mg/kg. |
| Administration: | IV daily for 4 days. |
| Result: | Exhibited anti-tumor activity. |
storage
Store at -20°C
References
[1] Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001 Nov;37(17):2275-82. DOI:10.1016/s0959-8049(01)00275-1
[2] Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. DOI:10.1016/j.bmcl.2003.09.062
IndisulamSupplier
- Tel
- 13549236410
- sales@invivochem.cn
- Tel
- sales@boylechem.com
- Tel
- +1 (866) 930-6790
- info@adooq.com
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- 025-58849295 18951903616;
- info@adooq.cn